Skip to main content

Seattle biotech Omeros selling drug franchise in deal valued at over $1B

The deal includes a $125 million upfront payment and a commercial milestone payment of $200 million for Omidria, a drug used in cataract surgery.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.